Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). - Pinto,C.; Di,F.Fabio.; Siena,S. (Ann Oncol, 2007)